Summary of findings 12. Secukinumab compared to placebo for chronic palmoplantar pustulosis.
| Secukinumab compared to placebo for chronic palmoplantar pustulosis | ||||||
| Patient or population: chronic palmoplantar pustulosis Setting: outpatients/hospital Intervention: secukinumab Comparison: placebo | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | No. of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Risk with placebo | Risk with secukinumab | |||||
| Proportion of participants cleared or almost clear ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | Not reported |
| Proportion of participants with adverse effects serious or severe enough to have caused withdrawal Follow‐up: over 16 weeks | Study population | RR 3.29 (1.40 to 7.75) | 157 (1 RCT) | ⊕⊕⊕⊝ Moderatea | ‐ | |
| 77 per 1 000 | 253 per 1 000 (108 to 596) | |||||
| Proportion of participants with at least 50% improvement in their quality of life ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | Not reported |
| Proportion of participants with a 50% reduction in disease severity assessed with PPPASI Follow‐up: 16 weeks | Study population | RR 1.55 (1.02 to 2.35) | 157 (1 RCT) | ⊕⊕⊕⊝ Moderatea | ‐ | |
| 295 per 1 000 | 457 per 1 000 (301 to 693) | |||||
| Proportion of participants without relapse in the long term ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | Not reported |
| Proportion of participants with adverse effects in the short term ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | Not reported |
| Ease of compliance to an intervention or a treatment ‐ not reported | ‐ | ‐ | ‐ | ‐ | ‐ | Not reported |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio. | ||||||
| GRADE Working Group grades of evidence. High quality: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate quality: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low quality: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low quality: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | ||||||
aDowngraded by one level to moderate‐quality evidence because of imprecision (only one trial).